Knowledge base
1,824 claims across 19 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,824ai alignment 395health 320internet finance 306space development 227entertainment 169grand strategy 141collective intelligence 52mechanisms 34teleological economics 30living agents 30cultural dynamics 29critical systems 24energy 23teleohumanity 18living capital 10robotics 5manufacturing 5technology 3unknown 3
an AI agent that is uncertain about its objectives will defer to human shutdown commands because corrigibility emerges from value uncertainty not from engineering against instrumental interests
Russell and collaborators (IJCAI 2017) prove a result that directly challenges Yudkowsky's framing of the corrigibility problem. In the Off-Switch Game, an agent that is uncertain about its utility function will rationally defer to a human pressing the off-switch. The mechanism: if the agent isn't s
eliciting latent knowledge from AI systems is a tractable alignment subproblem because the gap between internal representations and reported outputs can be measured and partially closed through probing methods
The Alignment Research Center's ELK (Eliciting Latent Knowledge) report, published in December 2021, formalizes one of alignment's core problems: an AI system's internal model may contain accurate information that its outputs don't faithfully report. This is the gap between what a model "knows" and
All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026
The UK House of Lords Science and Technology Committee launched its NHS AI inquiry on March 10, 2026, with explicit framing as an adoption failure investigation: 'Why does the NHS adoption of the UK's cutting-edge life sciences innovations often fail, and what could be done to fix it?' The inquiry e
Regulatory vacuum emerges when deregulation outpaces safety evidence accumulation creating institutional epistemic divergence between regulators and health authorities
The simultaneous release of the EU Commission's proposal to ease AI Act requirements for medical devices and WHO's explicit warning of 'heightened patient risks due to regulatory vacuum' documents a regulator-vs.-regulator split at the highest institutional level. The Commission proposed postponing
US healthspan declined from 65.3 to 63.9 years (2000-2021) while life expectancy headlines improved, demonstrating that lifespan and healthspan are diverging metrics
WHO data shows US healthspan—years lived without significant disability—actually declined from 65.3 years in 2000 to 63.9 years in 2021, a loss of 1.4 healthy years. This occurred during the same period when life expectancy fluctuated but ultimately reached a record high of 79 years in 2024 accordin
Tirzepatide's patent thicket extending to 2041 bifurcates the GLP-1 market into a commodity tier (semaglutide generics, $15-77/month) and a premium tier (tirzepatide, $1,000+/month) from 2026-2036
Tirzepatide's patent protection extends significantly beyond semaglutide through a deliberate thicket strategy: primary compound patent expires 2036, with formulation and delivery device patents extending to approximately December 30, 2041. This contrasts sharply with semaglutide, which expired in I
LLM anchoring bias causes clinical AI to reinforce physician initial assessments rather than challenge them because the physician's plan becomes the anchor that shapes all subsequent AI reasoning
The GPT-4 anchoring study finding that 'incorrect initial diagnoses consistently influenced later reasoning' provides a cognitive architecture explanation for the clinical AI reinforcement pattern observed in OpenEvidence adoption. When a physician presents a question with a built-in assumption or i
Clinical AI that reinforces physician plans amplifies existing demographic biases at population scale because both physician behavior and LLM training data encode historical inequities
The Nature Medicine finding that LLMs exhibit systematic sociodemographic bias across all model types creates a specific safety concern for clinical AI systems designed to 'reinforce physician plans' rather than replace physician judgment. Research on physician behavior already documents demographic
Ultra-processed food consumption increases incident hypertension risk by 23% over 9 years through a chronic inflammation pathway that establishes food environment as a mechanistic driver not merely a poverty correlate
The REGARDS cohort tracked 5,957 adults free from hypertension at baseline for 9.3 years (2003-2016). Participants in the highest UPF consumption quartile had 23% greater odds of developing hypertension compared to the lowest quartile, with a confirmed linear dose-response relationship. 36% of the i
The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity
The Mayo Clinic study examined healthspan-lifespan gaps across 183 WHO member states from 2000-2019 and found the United States has the largest gap globally at 12.4 years—meaning Americans live on average 12.4 years with significant disability and sickness. This exceeds other high-income nations: Au
Multi-agent clinical AI is being adopted for efficiency reasons not safety reasons, creating a situation where NOHARM's 8% harm reduction may be implemented accidentally via cost-reduction adoption
The Mount Sinai paper frames multi-agent clinical AI as an EFFICIENCY AND SCALABILITY architecture (65x compute reduction), while NOHARM's January 2026 study showed the same architectural approach reduces clinical harm by 8% compared to solo models. The Mount Sinai paper does not cite NOHARM's harm
CVD mortality stagnation after 2010 affects all income levels including the wealthiest counties indicating structural system failure not poverty correlation
The pervasive nature of CVD mortality stagnation across all income deciles—including the wealthiest counties—demonstrates this is a structural, system-wide phenomenon rather than a poverty-driven outcome. While county-level median household income was associated with the absolute level of CVD mortal
US CVD mortality is bifurcating with ischemic heart disease declining while heart failure and hypertensive disease reach all-time highs revealing that aggregate improvement masks structural deterioration in cardiometabolic health
The AHA 2026 report reveals a critical bifurcation in CVD mortality trends. While overall age-adjusted CVD mortality declined 33.5% from 1999 to 2023 (350.8 to 218.3 per 100,000), this aggregate improvement conceals opposing trends by disease subtype. Ischemic heart disease and cerebrovascular disea
CVD mortality stagnation drives US life expectancy plateau 3-11x more than drug deaths inverting the dominant opioid crisis narrative
NCI researchers quantified the contribution of different mortality causes to US life expectancy stagnation between 2010 and 2017. CVD stagnation held back life expectancy at age 25 by 1.14 years in both women and men. Rising drug-related deaths had a much smaller effect: 0.1 years in women and 0.4 y
Medical benchmark performance does not predict clinical safety as USMLE scores correlate only 0.61 with harm rates
The NOHARM study found that safety performance (measured as severe harm rate across 100 real clinical cases) correlated only moderately with existing AI and medical benchmarks at r = 0.61-0.64. This means that a model's USMLE score or performance on other medical knowledge tests explains only 37-41%
Provider tax freeze blocks state CHW expansion by eliminating the funding mechanism not the program because provider taxes fund 17 percent of state Medicaid share and CHW SPAs require state match
The OBBBA provider tax freeze creates a structural contradiction for CHW expansion: 20 states now have federal SPA approval for CHW reimbursement (as of March 2025), but provider taxes fund 17%+ of state Medicaid share nationally (30%+ in Michigan, NH, Ohio). States are prohibited from establishing
Ultra-processed food diets generate continuous inflammatory vascular damage that partially counteracts antihypertensive pharmacology explaining why 76.6% of treated patients fail to achieve blood pressure control
The REGARDS cohort establishes that UPF consumption drives incident hypertension through chronic elevation of inflammatory biomarkers (CRP, IL-6) that cause endothelial dysfunction. In food-insecure households, this creates a circular mechanism: (1) limited access to affordable non-UPF foods forces
Hypertension became the primary contributing cardiovascular cause of death in the US since 2022 marking a shift from acute ischemia to chronic metabolic disease as the dominant CVD mortality driver
Hypertensive disease age-adjusted mortality doubled from 15.8 to 31.9 per 100,000 between 1999-2023. Since 2022, hypertension has become the #1 contributing cardiovascular cause of death in the US, surpassing ischemic heart disease. This represents a fundamental epidemiological shift: the primary dr
LLM-generated nursing care plans exhibit dual-pathway sociodemographic bias affecting both plan content and expert-rated clinical quality
A cross-sectional simulation study published in JMIR (2025) generated 9,600 nursing care plans using GPT across 96 sociodemographic identity combinations and found systematic bias operating through two distinct pathways. First, the thematic content of care plans varied by patient demographics—what t
EU Commission's December 2025 medical AI deregulation proposal removes default high-risk AI requirements shifting burden from requiring safety demonstration to allowing commercial deployment without mandated oversight
The European Commission's December 2025 proposal amends the AI Act so that AI medical devices remain within scope but are no longer subject to high-risk AI system requirements by default. The Commission retained only the power to adopt delegated or implementing acts to reinstate those requirements—n
FDA transparency requirements treat clinician ability to understand AI logic as sufficient oversight but automation bias research shows trained physicians defer to flawed AI even when they can understand its reasoning
The FDA's 2026 CDS Guidance places greater emphasis on transparency regarding data inputs, underlying logic, and how recommendations are generated. FDA explicitly noted concern about 'how HCPs interpret CDS outputs'—acknowledging automation bias exists—but treats transparency as the solution. The gu
CVD mortality stagnation after 2010 reversed a decade of Black-White life expectancy convergence because structural cardiovascular improvements drove racial health equity gains more than social interventions
Between 2000-2009, CVD mortality declined faster for Black Americans than White Americans, narrowing the Black-White life expectancy gap by 1.39 years for women and 1.44 years for men. After 2010, this convergence stopped. Counterfactual analysis shows that if pre-2010 CVD trends had continued throu
Tailored digital health interventions achieve clinically significant systolic BP reductions at 12 months in US populations experiencing health disparities, but the effect is conditional on design specificity for these populations rather than generic deployment
A systematic review and meta-analysis of 28 studies covering 8,257 patients found that digital health interventions produced clinically significant reductions in systolic blood pressure at both 6 and 12 months in populations experiencing health disparities (racial/ethnic minorities, low-income adult
Indian generic semaglutide exports enabled by evergreening rejection create a global access pathway before US patent expiry
The Delhi High Court division bench rejected Novo Nordisk's attempt to block Dr. Reddy's from exporting semaglutide, specifically citing concerns about 'evergreening and double patenting strategies.' This ruling is structurally significant because it removes the legal risk Indian manufacturers faced
Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation
The distinction between stagnation and reversal is critical for understanding the severity of the post-2010 health crisis. While old-age CVD mortality (ages 65-84) continued declining but at a much slower pace, many states experienced outright increases in midlife CVD mortality (ages 40-64) during 2
Page 33 of 73